ASH 2018 | Flow cytometry vs. NGS testing for determining MRD negativity in patients with ALL

Stephan Grupp

Stephan Grupp, MD, PhD, of the Children’s Hospital of Philadelphia, Philadelphia, PA, speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, discusses the use of flow cytometry and NGS testing for determining MRD negativity in patients with acute lymphoblastic leukemia (ALL).

Share this video